FLT3 and acute myeloid leukemia: Recent phase 3 clinical trials investigated the clinical outcome of AML patients at relapse following treatment with such FLT3 tyrosine kinase inhibitors (TKI) as quizartinib or gilteritinib compared with intensive salvage chemotherapy regimens.